Oncorus, Inc.
ONCR
ONCR was delisted on the 20th of June, 2023.
1 hedge funds and large institutions have $3 invested in Oncorus, Inc. in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
75% less funds holding
Funds holding: 4 → 1 (-3)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $212K → $3 (-$212K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$115K |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$96.3K |
| 3 |
Barclays
London,
United Kingdom
|
-$384 |
ONCR Hedge Fund Activity: Q3 2023 in Review
1 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Oncorus, Inc. (ONCR) for Q3 2023, worth a combined $3 — down 100% from $212K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ONCR and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was MPM Asset Management, exiting entirely with an estimated $115K sold.
- 1 institutional investor held Oncorus, Inc. (ONCR) as of Q3 2023, down from 4 in Q2 2023.
- Funds reported $3 of Oncorus, Inc. stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Oncorus, Inc. positions in Q3 2023 and 3 closed out, a net change of -3 holders.
- The largest Oncorus, Inc. seller in Q3 2023 was MPM Asset Management, an estimated $115K sold.
Based on aggregated 13F filings for Q3 2023.